Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels in New Jersey
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
New Jersey Pricing in Context
In New Jersey, CPT code 37185 (Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels) carries an average Medicare payment of $182.51 — 24% above the national benchmark of $147.30. 72 providers across the state submitted claims for this procedure in 2023, performing 158 total services. Individual payments in NJ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in New Jersey is $3,089.68, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New Jersey sits above the national Medicare average, commercial rates in the state may also run higher than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Cardiovascular Surgery procedures, the estimated commercial insurance price in New Jersey lands near $583.24, with self-pay cash prices typically around $1,021.20. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels cost in New Jersey?
The average Medicare payment for Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels in New Jersey is $182.51, which is 24% above the national average of $147.30. Providers in NJ typically bill $3,089.68 for this procedure.
What does Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels cost with insurance in New Jersey?
With commercial insurance in New Jersey, Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels costs an estimated $583.24. Without insurance, the estimated cash price is $1,021.20. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels in New Jersey?
72 providers in New Jersey billed Medicare for Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels in 2023, performing 158 total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels cheaper in New Jersey than the national average?
No — Primary Removal And Dissolving Of Blood Clot From Artery Or Artery Graft Using Fluoroscopic Guidance, Subsequent Vessels costs 24% above the national average in New Jersey. The state average Medicare payment is $182.51 compared to $147.30 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.